PHARMA LITERATI

A new book has been published recently. The details for the same are as  follows :  Author:   Dr. Manthan Janodia, Asso. Professor, Department of Pharmacy Management, MCOPS, Manipal University. Please see:  http://manipal.edu/mcops-manipal/department-faculty/faculty-list/manthan-d-janodia.html Review: This book on Intellectual Property Rights (IPRs), aimed at undergraduate and post graduate students, research scholars and faculty members. The objective is to sensitize undergraduate and post graduate students regarding various aspects of IPRs, provide guidance to research scholars regarding safeguards to put in place for potentially patentable research and serve as a ready reckoner to faculty members interested to apply for patents but do not have a comprehensive information in various aspects of filing a patent application. The book does not aim to complicate already complex issue of patent but simplifies various concepts through hypothetical exam...

Government plans to sell more than 400 generic medicines at cheaper price through Jan Aushadhi stores by end of this year. At present, there are 225 generic medicines available at Jan Aushadhi store. The rates of medicine on these stores are as low as one-third to one-tenth of the market price depending on the type of medicine. Ahir said the ministry will provide quality generic medicines to all, especially the poor, including medicines used for treating diabetes, cancer and cardiovascular diseases. Speaking while inaugurating the Jan Aushadhi store Ahir said, "We will increase the number of generic medicines to 425 from 225 at present which will also include medicines treating for diabetes and cancer among others." The government is also planning to increase the number Jan Aushadhi stores to 3,000 that will be opened in two years across the country by involving B Pharma and M Pharma qualified unemployed populace. The government has been selling generic medicines at ...

December 3, 2015, Dehradun, Uttarakhand  January 28, 2016; Gangtok, Sikkim March 16, 2016, Panji, Goa India's Pharma industry has been at the forefront of the public health revolution to make medicines affordable. Generic drug manufacturers in India have lowered prices of a range of therapeutics and saved millions of lives. But time and gain various doubts have been raised about the quality of medicines manufactured in India which has not only threatened domestic production but also exports which is the prime commodity exported by India. Good Manufacturing Practice is that part of quality management which ensures that products are consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization, clinical trial authorization or product specification. GMP is concerned with both production and QC. Fact about Current Good Manufacturing Practices (cGMP) is aimed primarily at managing ...

An indigenous diagnostic kit for tuberculosis is undergoing the final stages of validation and is expected to bring down the cost of diagnosing TB significantly. This was stated by the Director General of the Indian Council for Medical Research (ICMR) , Dr Soumya Swaminathan, at a symposium on intellectual property in India organised by the Swiss Embassy. The new kit is a joint initiative of the Department of Bio-Technology (DBT), ICMR and the health ministry. "The health ministry is looking for diagnostics of high quality that is also affordable," said Dr Swaminathan. Referring to the recent controversy in the US where a company that had a monopoly over a crucial drug hiked its price by 5,500%, Dr Swaminathan said India had to be mindful that companies had that kind of power. The symposium was dominated by those representing Big Pharma interests who emphasised the high costs of drug discovery based on a study by a research centre heavily funded by the pharma indu...

This is 350 th post for pharma literati. There are lots of activities happening with reference to our beloved blog. Here is a quick recap of the activities for those who have subscribed us recently: Collaborations: FICCI – CCIPR http://pharmaliterati.blogspot.in/2015/06/pharma-literati-collaborates-with-ficci.html Pharma career http://pharmaliterati.blogspot.in/2015/06/collaboration-with-pharmacareer.html Social Media presence: LinkedIn http://pharmaliterati.blogspot.in/2015/06/pharma-literati-on-linkedin.html Mobile app http://pharmaliterati.blogspot.in/2015/06/pharma-literati-available-on-mobile-app.html Facebook http://pharmaliterati.blogspot.in/2015/07/pharma-literatinow-has-facebook-page.html WhatsAPP 09769059971 Issuu http://www.issuu.com/pharmaliterati/ Subscription information: Subscriptions 250+ sub...

Better late than never. The delay for publication is because of the vacation.  The November, 2015 issue of Pharma Literati Magazine is available now. Please visit the same at:  http://issuu.com/pharmaliterati/docs/november_2015_magazine The collaborators and the subscribers who have requested e-copy would get the PDF version of the same via email over next two days. The faculties/ researchers/ students are requested to share it via e-platforms and/or notice board. 

Four years after the last buyout, more Indian pharmaceutical firms are eyeing acquisition opportunities in Japan, the world’s second largest drug market. Except Mumbai-based Lupin Ltd, which made its second buyout in 2011 in Japan, none of the Indian drug makers have been able to establish a footprint in the $115-billion Japanese pharma market. Last Friday, ET Now television news channel said Sun Pharmaceuticals Industries Ltd was planning to acquire the Japanese drug portfolio of Swiss firm Novartis to make its entry into Japan.  Sun Pharma, which acquired Ranbaxy Ltd for $4 billion last year, also plans to raise up to Rs.12,000 crore through convertible debentures or a qualified institutional placement (QIP) for expansion and acquisitions. Japan, where drug sales were estimated at $115 billion in 2013, accounts for nearly 10% of the global pharma market, compared with 38.4% for the US and 20.7% for western Europe, according to a 2014 Deloitte report. “The ...